Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.
2.

Effects of garlic on dyslipidemia in patients with type 2 diabetes mellitus.

Ashraf R, Aamir K, Shaikh AR, Ahmed T.

J Ayub Med Coll Abbottabad. 2005 Jul-Sep;17(3):60-4.

PMID:
16320801
3.

The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study.

Miller M, Dobs A, Yuan Z, Battisti WP, Palmisano J.

Curr Med Res Opin. 2006 Feb;22(2):343-50.

PMID:
16466606
4.

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.

Clin Ther. 2007 Jul;29(7):1354-67.

PMID:
17825687
5.

Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis.

Saltissi D, Morgan C, Rigby RJ, Westhuyzen J.

Am J Kidney Dis. 2002 Feb;39(2):283-90.

PMID:
11840368
6.

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.

Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-Garcia AB, Grundy SM.

Am J Cardiol. 2003 Apr 15;91(8):956-60.

PMID:
12686335
7.

One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.

Ferdinand KC, Davidson MH, Kelly MT, Setze CM.

Am J Cardiovasc Drugs. 2012 Apr 1;12(2):117-25. doi: 10.2165/11597940-000000000-00000.

PMID:
22263674
8.

Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.

Lewin AJ, Kipnes MS, Meneghini LF, Plotkin DJ, Perevozskaya IT, Shah S, Maccubbin DL, Mitchel YB, Tobert JA; Simvastatin/Thiazolidinedione Study Group.

Clin Ther. 2004 Mar;26(3):379-89.

PMID:
15110130
9.

Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group.

Ose L, Davidson MH, Stein EA, Kastelein JJ, Scott RS, Hunninghake DB, Campodonico S, Insull W, Escobar ID, Schrott HG, Stepanavage ME, Wu M, Tate AC, Melino MR, Mercuri M, Mitchel YB.

Clin Cardiol. 2000 Jan;23(1):39-46.

10.

Comparison of the efficacy and safety profile of morning administration of controlled-release simvastatin versus evening administration of immediate-release simvastatin in chronic kidney disease patients with dyslipidemia.

Yi YJ, Kim HJ, Jo SK, Kim SG, Song YR, Chung W, Han KH, Lee CH, Hwang YH, Oh KH.

Clin Ther. 2014 Aug 1;36(8):1182-90. doi: 10.1016/j.clinthera.2014.06.005. Epub 2014 Jul 2.

11.

Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.

Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR.

Am J Cardiol. 2008 Aug 15;102(4):429-33. doi: 10.1016/j.amjcard.2008.03.078. Epub 2008 May 22. Erratum in: Am J Cardiol. 2008 Nov 15;102(10):1425.

PMID:
18678300
12.

Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.

Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M; LCP-AtorFen Investigators.

Clin Ther. 2009 Dec;31(12):2824-38. doi: 10.1016/j.clinthera.2009.12.007.

PMID:
20110022
13.

Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).

May HT, Anderson JL, Pearson RR, Jensen JR, Horne BD, Lavasani F, Yannicelli HD, Muhlestein JB.

Am J Cardiol. 2008 Feb 15;101(4):486-9. doi: 10.1016/j.amjcard.2007.09.095. Epub 2007 Dec 26.

PMID:
18312763
14.

A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.

Olsson AG, Eriksson M, Johnson O, Kjellström T, Lanke J, Larsen ML, Pedersen T, Tikkanen MJ, Wiklund O; 3T Study Investigators.

Clin Ther. 2003 Jan;25(1):119-38.

PMID:
12637115
15.

Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.

Hunninghake DB, Ballantyne CM, Maccubbin DL, Shah AK, Gumbiner B, Mitchel YB.

Clin Ther. 2003 Jun;25(6):1670-86.

PMID:
12860491
18.

Ameliorative effects of Nigella sativa on dyslipidemia.

Asgary S, Sahebkar A, Goli-Malekabadi N.

J Endocrinol Invest. 2015 Oct;38(10):1039-46. doi: 10.1007/s40618-015-0337-0. Epub 2015 Jul 2. Review.

PMID:
26134064
19.

[Lipid intervention and coronary heart disease in men less than 56 years of age. The Coronary Intervention Study: CIS].

Rensing UF, Bestehorn HP, Roskamm H, Petersen J, Betz P, Spinder M, Benesch L, Schemeitat K, Blümchen G, Claus J, Wieland H, Böcker JF, Neiss A, Stiepel E, Mathes P, Kappenberger L, Braunagel K, Peters K, Meister G, Samek L, Schuon J, Leimenstoll B, Kiefer H.

Z Kardiol. 1999 Apr;88(4):270-82. German.

PMID:
10408031
20.

Supplemental Content

Support Center